Ikatibant Alpha-Medical

Icatibant, the active ingredient in Ikatibant Alpha-Medical, is a bradykinin B2 receptor antagonist presented as a subcutaneous injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with C1‑inhibitor deficiency. GNH USA supplies Ikatibant Alpha-Medical as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage conditions driven by excessive bradykinin activity, especially hereditary angioedema.

Hereditary angioedema (C1‑inhibitor deficiency) attacks: reduces swelling and pain during acute episodes.

Icatibant may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or swelling at injection site: localized inflammatory response. - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Dizziness: occasional light‑headed sensation.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Angioedema of the airway: potential respiratory compromise. - Hypotension: sudden drop in blood pressure. - Thrombocytopenia: reduced platelet count. - Severe injection site necrosis: tissue damage at the injection site.

Before using Ikatibant, consider the following safety measures. - Assess hypersensitivity: avoid in patients with known allergy to icatibant or formulation components. - Monitor airway: watch for signs of airway obstruction during acute attacks. - Use with caution in pregnancy: safety data are limited; evaluate risk‑benefit. - Evaluate renal or hepatic impairment: adjust monitoring as needed. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant may interact with other medications that influence bradykinin pathways or vascular tone.

Major Interactions (Avoid): - ACE inhibitors: can increase bradykinin levels and exacerbate swelling. - Other bradykinin B2 antagonists: concurrent use may lead to unpredictable effects.

Moderate Interactions (Monitor Closely): - Estrogen‑containing contraceptives: may increase frequency of HAE attacks. - Diuretics: monitor blood pressure and electrolyte balance. - Antihistamines: may mask early signs of allergic reactions.